Cytomx Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Cytomx Therapeutics Inc 's ROA in the second quarter of 2026?
Cytomx Therapeutics Inc recorded a cumulative net loss of $-80 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -30.32%.

However, within the Healthcare sector 425 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3607, from total ROA ranking in the first quarter of 2026 at 3825.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	118.11 %	264.84 %	25.75 %	13.87 %	9.95 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-80	-59	-17	28	48
Return On Assets (TTM)	-30.32 %	-28.02 %	-11.91 %	20.29 %	36.01 %
CTMX's Total Ranking	# 3607	# 3825	# 234	# 114	# 132
Total Assets (TTM) in million	382	359	152	158	175
Seq. Total Assets Change	6.25 %	137.1 %	-4.23 %	-9.6 %	77.73 %
Seq. Net Income Change	-	-	-	-	-

CTMX's 5 Years Annual ROA >> Back to CTMX Management Effectiveness >> Compare CTMX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 165
Sector	# 426
Overall	# 3611

Return On Assets Statistics
High	Average	Low
36.01 %	-16.78 %	-45.39 %
(Jun 30 2025)		(Dec 31 2022)

Financial Statements
Cytomx Therapeutics Inc 's Assets	$ 382 million	CTMX's Balance sheet
Cytomx Therapeutics Inc 's Income	$ -21 million	Quarterly CTMX's Income Statement
CTMX's Income by Division		See CTMX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	25.75 %	-40.27 %	-22.65 %	-23.13 %	-5.37 %
Total Assets in million	152	121	202	261	339
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-17	32	-1	-99	-116
Annual Return On Assets	-11.46 %	26.44 %	-0.28 %	-38.07 %	-34.14 %

CTMX's 5 Years Annual ROA >> Back to CTMX Management Effectiveness >> Compare CTMX ROA to its Competitors

More Return On Assets Ratios
CTMX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CTMX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CTMX's Competitors
Subscribers only: Roa for Cytomx Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for CTMX's Customers

You may also want to know
CTMX's Roi	CTMX's Inventory Turnover Ratio	CTMX's Growth Rates	CTMX's Dividend Comparisons
	CTMX's Profitability Ratios	CTMX's Asset Turnover Ratio	CTMX's Dividend Growth
CTMX's Roe	CTMX's Valuation Ratios	CTMX's Financial Strength Ratios	CTMX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T01:13:00+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.